One year in review 2020: gout

L Punzi, A Scanu, P Galozzi, R Luisetto… - Clinical and …, 2020 - boa.unimib.it
Gout is the most prevalent form of inflammatory arthritis, with a strong impact on individual
health and healthcare systems. This article reviews clinical and experimental evidences …

What are the core recommendations for gout management in first line and specialist care? Systematic review of clinical practice guidelines

B Conley, S Bunzli, J Bullen, P O'Brien, J Persaud… - BMC rheumatology, 2023 - Springer
Background Gout is the most common inflammatory arthritis, increasing in prevalence and
burden. Of the rheumatic diseases, gout is the best-understood and potentially most …

[PDF][PDF] The Clinical Problem Gout is a chronic disease of monosodium urate deposition char-acterized by arthritis flares and disability. Lasting days to weeks if un

TR Mikuls - N Engl J Med, 2022 - internetbookofemergencymedicine …
treated, flares are inflammatory, often intensely painful, and debilitating. Separated by
asymptomatic intercritical periods, flares can increase in frequency and severity over time …

An evidence review of low-value care recommendations: inconsistency and lack of economic evidence considered

DD Kim, LA Do, AT Daly, JB Wong… - Journal of General …, 2021 - Springer
Background Low-value care, typically defined as health services that provide little or no
benefit, has potential to cause harm, incur unnecessary costs, and waste limited resources …

Consistency of recommendations for pharmacotherapy of rheumatoid arthritis

Y Hu, Y Han, Y Ma, S Fan, X Wang, X Fu… - Frontiers in …, 2022 - frontiersin.org
Background: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory arthropathy.
Recommendations for RA, specifically on pharmacotherapy, are essential in clinical …

A Phase I Study to Evaluate the Pharmacokinetic Drug‒Drug Interaction of HP501, Febuxostat, and Colchicine in Male Chinese Patients with Hyperuricemia

R Ding, L Chen, X Li, T Xiong, H Chen, X Hu… - Clinical Drug …, 2023 - Springer
Background and Objective HP501 is a highly selective renal urate transporter 1 (URAT1)
inhibitor that is being developed for the treatment of hyperuricemia and gout. The primary …

Plasma Fibronectin as a Novel Predictor of Coronary Heart Disease: A Retrospective Study

L Peng, H Deng, J Li, G Lu, YS Zhai - Journal of Cardiovascular …, 2023 - mdpi.com
Although fibronectin has been associated with the pathogenesis of atherosclerosis, little is
currently known about the relationship between plasma fibronectin and coronary heart …

[PDF][PDF] 基于NF-κB/IκBα 信号通路探讨“通经利浊” 针法对急性痛风性关节炎大鼠保护作用的机制研究

齐伟, 李丽, 张岳, 穆双双, 胡德, 王淑敏… - 中国比较医学 …, 2021 - zgbjyx.cnjournals.com
目的本研究旨在探讨“通经利浊” 针法对急性痛风性关节炎大鼠潜在的保护机制.
方法模型组通过注射单钠尿酸盐(MSU) 诱发大鼠急性痛风性关节炎. 治疗组对大鼠进行“通经利 …

Reporting quality of clinical practice guidelines regarding gout and hyperuricemia according to the RIGHT checklist: systematic review

C Wang, X Luo, M Li, L Cui, X Li, L Han, X Wang… - Systematic …, 2021 - Springer
Abstract Background The Reporting Items for Practice Guidelines in Healthcare (RIGHT)
checklist was used to assess the reporting quality of 2009–2019 clinical practice guidelines …

[PDF][PDF] Impact of disease duration and gender on the sensitivity and specificity of 2015 ACR/EULAR classification criteria for gout. Cross-sectional results from an …

M Lorenzin, N Ughi, A Ariani, B Raffeiner… - Clin Exp …, 2021 - clinexprheumatol.org
Objective We aimed to assess the performance of the 2015 American College of
Rheumatology/European League Against Rheumatism (ACR/EULAR) gout classification …